September 16, 2016 10:49 AM EDT

Thumbs Up/Thumbs Down: The UN fumbles badly over access to drugs while developers think again about R&D strategies

Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

view job offer post your job now

TRENDING NOW

Thumbs Up/Thumbs Down: The UN fum­bles bad­ly over ac­cess to drugs while de­vel­op­ers think again about R&D strate­gies